Carl H. Sadowsky, MD

This review follows the progress of rivastigmine over the years, from the basics of its pharmacology and key historic clinical milestones with oral capsules, to the rationale for transdermal...

This retrospective analysis aimed to identify the percentage of individuals with Alzheimer's disease who have a sustained response with rivastigmine patch, rivastigmine capsules, or placebo.

This study evaluates the long-term safety, tolerability, and efficacy of switching from donepezil to rivastigmine transdermal patches in patients with mild to moderate Alzheimer's disease.